Trials / Unknown
UnknownNCT04958252
A Study in Healthy Japanese Men to Test How Different Doses of BI 1569912 Are Taken up by the Body and How Well They Are Tolerated
Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses and Multiple Oral Doses of BI 1569912 in Healthy Male Japanese Subjects (Single-blind, Partially Randomised Within Dose Groups, Placebo-controlled, Parallel-group Design)
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety and tolerability of BI 1569912 in healthy male Japanese subjects following oral administration of single rising doses and multiple doses. Secondary objective is the exploration of pharmacokinetics (PK) of BI 1569912.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 1569912 | BI 1569912 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2021-08-05
- Primary completion
- 2023-10-24
- Completion
- 2023-10-24
- First posted
- 2021-07-12
- Last updated
- 2023-10-19
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04958252. Inclusion in this directory is not an endorsement.